China Oncology

30 December 2022, Volume 32 Issue 12 Previous Issue Next Issue

Cover and contents

2022 Issue 12 Cover

Abstract ( 105) PDF (3144KB) ( 300 )

Contents of Issue 12, 2022

2022, 32 (12): 2-2.

Abstract ( 72) PDF (16285KB) ( 215 )

Specialists' Commentary

Current status and prospect of perioperative treatment of stage Ⅲ melanoma

XU Yu, CHEN Yong, YANG Jilong, ZHU Guannan

2022, 32 (12): 1133-1146. doi: 10.19401/j.cnki.1007-3639.2022.12.001

Abstract ( 274) PDF (1355KB) ( 1175 ) HTML ( 30 )

Specialists' Article

Adjuvant therapy with anti-PD-1 antibody vs targeted therapy for patients with resected stage Ⅲ malignant melanoma: a real-world data analysis from China centers

LI Ting, XU Yu, JIA Dongdong, LIAO Zhichao, SUN Wei, WU Haixiao, REN Zhiwu, ZHAO Jun, XING Ruwei, TENG Sheng, YANG Yun, CHEN Yong, LI Tao, YANG Jilong

2022, 32 (12): 1147-1157. doi: 10.19401/j.cnki.1007-3639.2022.12.002

Abstract ( 313) PDF (1611KB) ( 1036 ) HTML ( 14 )

Multivariable prognostic analyses of Chinese acral and cutaneous melanoma after surgical treatment for the past five years in a single cancer center

LIN Xinyi, SUN Wei, HU Tu, WANG Chunmeng, YAN Wangjun, LUO Zhiguo, LIU Xin, ZHONG Jingqin, ZOU Zijian, XU Yu, CHEN Yong

2022, 32 (12): 1158-1167. doi: 10.19401/j.cnki.1007-3639.2022.12.003

Abstract ( 257) PDF (1451KB) ( 1026 ) HTML ( 18 )

Clinical value of sentinel lymph node biopsy in patients with cutaneous and acral melanoma

ZOU Zijian, SUN Wei, HU Tu, WANG Chunmeng, YAN Wangjun, LUO Zhiguo, LIU Xin, ZHONG Jingqin, LIN Xinyi, XU Yu, CHEN Yong

2022, 32 (12): 1168-1177. doi: 10.19401/j.cnki.1007-3639.2022.12.004

Abstract ( 174) PDF (1512KB) ( 982 ) HTML ( 5 )

Retrospective analysis of adjuvant therapy with dabrafenib and trametinib for 24 patients with malignant melanoma

JIA Dongdong, LI Tao

2022, 32 (12): 1178-1183. doi: 10.19401/j.cnki.1007-3639.2022.12.005

Abstract ( 210) PDF (1328KB) ( 949 ) HTML ( 7 )

Article

Characteristics and prognostic analysis of oral mucosal melanoma with lung metastasis

HAN Ruxue, LIANG Xiang, MA Xuhui, GUO Wei, WU Yunteng, REN Guoxin

2022, 32 (12): 1184-1189. doi: 10.19401/j.cnki.1007-3639.2022.12.006

Abstract ( 227) PDF (1312KB) ( 1075 ) HTML ( 23 )

Expression of MMR in 515 cases of endometrioid adenocarcinoma and its correlation with clinicopathological features

WU Quan, GUO Jingwei, LEI Yuxin, HU Xiaoru, WANG Zhe

2022, 32 (12): 1190-1198. doi: 10.19401/j.cnki.1007-3639.2022.12.007

Abstract ( 210) PDF (1868KB) ( 1069 ) HTML ( 6 )

Experimental study on influence of autophagy on DPD expression and its effect on chemotherapy with 5-FU in colorectal cancer

CUI Zhongze, HE Shuang, WEN Feifei, LI Yangyang, XU Xiaoyang, LU Lizhen, WU Shuhua

2022, 32 (12): 1199-1209. doi: 10.19401/j.cnki.1007-3639.2022.12.008

Abstract ( 160) PDF (3474KB) ( 480 ) HTML ( 6 )

Development and validation of a nomogram for predicting spread through air spaces in stage ⅠA lung adenocarcinoma

ZHANG Longfu, LIU Jie, NI Zheng, LU Xinyuan, HU Bin, WANG Hao, FENG Mingxiang, ZHANG Yong

2022, 32 (12): 1210-1217. doi: 10.19401/j.cnki.1007-3639.2022.12.009

Abstract ( 168) PDF (1420KB) ( 456 ) HTML ( 2 )

Glioma stem cell-derived exosomal lncRNA HOXA-AS2 promoted proliferation, migration, invasion and stemness in glioma

LIAO Xinghe, LIU Zhantao, LIU Minghui

2022, 32 (12): 1218-1228. doi: 10.19401/j.cnki.1007-3639.2022.12.010

Abstract ( 217) PDF (2114KB) ( 537 ) HTML ( 5 )

Prognostic value of perineural invasion in ypⅠ-Ⅱ rectal cancer patients who received neoadjuvant radiotherapy

WANG Jun, HE Ping

2022, 32 (12): 1229-1234. doi: 10.19401/j.cnki.1007-3639.2022.12.011

Abstract ( 130) PDF (1310KB) ( 467 ) HTML ( 2 )

Review

Research progress and prospect of Siglec in innate immune cells in tumor

GUO Zhaoyang, HU Jingzhou

2022, 32 (12): 1235-1241. doi: 10.19401/j.cnki.1007-3639.2022.12.012

Abstract ( 197) PDF (1229KB) ( 484 ) HTML ( 8 )

Guideline and Consensus

Chinese Prostate Cancer Consortium (CPCC) Chinese expert consensus on advanced prostate cancer: clinical management of patients with metastatic hormone-sensitive prostate cancer treated by initial novel hormone therapy (2022 edition)

Chinese Prostate Cancer Consortium (CPCC), YE Dingwei, HUANG Jian

2022, 32 (12): 1242-1258. doi: 10.19401/j.cnki.1007-3639.2022.12.013

Abstract ( 550) PDF (1291KB) ( 1077 ) HTML ( 36 )

Database Indexing

A Guide to the Core Journals of China
Chinese Science Citation Database (CSCD)
China National Knowledge Infrastructure (CNKI)
Chinese Sci-tech Paper and Citation Database (CSTPCD)
Outsanding S&T Journals of China (2020) (F5000)
World Journal Clout Index (WJCI) Report of Scientific and Technological Periodicals (2021)
SCOPUS
EMBASE
DOAJ
Chemical Abstracts (CA)
Japan Science and Technology Database (JST)
The Western Pacific Region Index Medicus (WPRIM)
EBSCO
Index of Copernicus International (ICI)

Competent Authorities

　The Ministry of Education of the People’s Republic of China

Sponsored by

　Fudan University Shanghai Cancer Center

Edited by

　Editorial Board of China Oncology

Editor-in-Chief

　SHAO Zhimin

Honorary Editor-in-Chief

　TANG Zhaoyou, CAO Shilong, SHEN Zhenzhou

Printed by

　Shanghai Ouyang Printing Co., Ltd.

WeChat